This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

Throughout its 40-year history, the field of gene therapy has been marked by many
transitions. It has seen great strides in combating human disease, has given hope to patients …

Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell
haematologic malignancies. The manufacturing of these T cells typically involves their …

HIV-1-infected cells that persist despite antiretroviral therapy (ART) are frequently
considered" transcriptionally silent," but active viral gene expression may occur in some …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of
infected individuals (here termed 'elite controllers'), despite the presence of a replication …

Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Transposable elements (TEs) are a prolific source of tightly regulated, biochemically active
non-coding elements, such as transcription factor-binding sites and non-coding RNAs. Many …

Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next
generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the …

Highly specific Cas9 nucleases derived from SpCas9 are valuable tools for genome editing,
but their wide applications are hampered by a lack of knowledge governing guide RNA …